@entity2120 40 mg/day (E) or fondaparinux 2.5 mg/day (F) are recommended to prevent @entity1211 ( @entity1211 ) in medical and surgical @entity1 at risk. Over the two years after switching from E to F in our 35-bed department of pulmonology and thoracic surgery, an increase in the number of transfusions was observed. A retrospective explanatory investigation was undertaken. Hospitalised @entity1 in the two years before and after switching from E to F were compared. The files of all transfused @entity1 were reviewed. A blinded independent committee adjudicated major @entity548 events. In the investigated time period, the overall transfusion rate increased from 1.8% of 2,989 @entity1 to 3.1% of 3,085 @entity1 (p=0.002). Mean ages (58.4 vs. 59.1 years), proportions of surgical @entity1 (63.6% vs. 58.4%), @entity5 @entity1 (72.1% vs. 69.5%), and treated @entity1 (>=  1 dose of E or F: 51.8% vs. 52.5%) were similar. The number of medical @entity1 transfused while receiving E or F did not increase significantly (0.9% vs. 1.3%, RR=1.45 [0.66-3.17], p=0.35). The number of surgical @entity1 transfused postoperatively while receiving E or F increased significantly (0.7% vs. 1.9% of all surgical @entity1 , relative risk [RR]=2.75 [1.45-5.23], p=0.001), including a significant increase in transfusions for major @entity548 (0.2% vs. 0.9%, RR=5.97 [1.74-20.4], p<0.001). A multivariate analysis did not find confounding factors. The incidence of symptomatic @entity1151 remained very low (0.05% vs. 0.17%). In conclusion, in thoracic surgery @entity1 , switching from enoxaparin to fondaparinux to prevent @entity1211 was associated with a significant increase in the risk of postoperative major @entity548 . A causal relationship appears plausible.

Transfusions, major XXXX , and prevention of @entity1211 with enoxaparin or fondaparinux in thoracic surgery.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['postoperative pulmonary embolism'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism'] @entity2120 :: ('MESH:D017984', 'Chemical') :: ['Enoxaparin']
@entity548 :: (MESH:D006470,Disease) :: ['bleeding']
